Business Description
![Fulcrum Therapeutics Inc Fulcrum Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000BN84.png?14)
Fulcrum Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US3596161097
Description
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 21.04 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 12.16 | |||||
Beneish M-Score | -2.83 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -49.1 | |||||
3-Year EBITDA Growth Rate | 13.5 | |||||
3-Year EPS without NRI Growth Rate | 17.1 | |||||
3-Year FCF Growth Rate | 11.7 | |||||
3-Year Book Growth Rate | 3.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 156.46 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 92.39 | |||||
9-Day RSI | 80.26 | |||||
14-Day RSI | 70.2 | |||||
6-1 Month Momentum % | 4.93 | |||||
12-1 Month Momentum % | 102.45 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 20.38 | |||||
Quick Ratio | 20.38 | |||||
Cash Ratio | 19.95 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -30.4 | |||||
Shareholder Yield % | 0.52 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -4484.38 | |||||
Net Margin % | -3961.2 | |||||
FCF Margin % | -3685.18 | |||||
ROE % | -38.96 | |||||
ROA % | -35.75 | |||||
ROIC % | -582.65 | |||||
ROC (Joel Greenblatt) % | -844.89 | |||||
ROCE % | -42.54 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 225.27 | |||||
PB Ratio | 2.62 | |||||
Price-to-Tangible-Book | 2.62 | |||||
EV-to-EBIT | -2.86 | |||||
EV-to-Forward-EBIT | -1.25 | |||||
EV-to-EBITDA | -2.91 | |||||
EV-to-Forward-EBITDA | -1.27 | |||||
EV-to-Revenue | 128.3 | |||||
EV-to-Forward-Revenue | 29.74 | |||||
EV-to-FCF | -3.19 | |||||
Price-to-Net-Current-Asset-Value | 2.82 | |||||
Price-to-Net-Cash | 2.88 | |||||
Earnings Yield (Greenblatt) % | -34.97 | |||||
FCF Yield % | -16.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FULC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fulcrum Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 2.51 | ||
EPS (TTM) ($) | -1.6 | ||
Beta | 3.36 | ||
Volatility % | 91.94 | ||
14-Day RSI | 70.2 | ||
14-Day ATR ($) | 0.466726 | ||
20-Day SMA ($) | 6.5925 | ||
12-1 Month Momentum % | 102.45 | ||
52-Week Range ($) | 3.14 - 13.7 | ||
Shares Outstanding (Mil) | 62.15 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Fulcrum Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Fulcrum Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Fulcrum Therapeutics Inc Frequently Asked Questions
What is Fulcrum Therapeutics Inc(FULC)'s stock price today?
The current price of FULC is $8.99. The 52 week high of FULC is $13.70 and 52 week low is $3.14.
When is next earnings date of Fulcrum Therapeutics Inc(FULC)?
The next earnings date of Fulcrum Therapeutics Inc(FULC) is 2024-08-02 Est..
Does Fulcrum Therapeutics Inc(FULC) pay dividends? If so, how much?
Fulcrum Therapeutics Inc(FULC) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |